Evidence map›Paper›PMID 40696437›Full record

ArticleMicrobiome2025

Interplay between the gut microbiome and typhoid fever: insights from endemic countries and a controlled human infection model.

Philip M Ashton, Leonardos Mageiros, James E Meiring, Angeziwa Chunga-Chirambo, Farhana Khanam, Sabina Dongol, Happy Banda, Abhilasha Karkey, Lorena Preciado-Llanes, Helena Thomaides-Brears and 23 more

Abstract read
In one paragraph

Article in Microbiome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The gut microbiome in early life predicts malaria susceptibility.Frontiers in cellular and infection microbiology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Philip M AshtonMalawi-Liverpool-Wellcome Programme, Blantyre, Malawi. flashton@gmail.com.
Leonardos Mageiros *Department of Infectious Diseases, School of Translational Medicine, Monash University, Melbourne, VIC, Australia.
James E Meiring *Malawi-Liverpool-Wellcome Programme, Blantyre, Malawi.
Angeziwa Chunga-Chirambo *Malawi-Liverpool-Wellcome Programme, Blantyre, Malawi.
Farhana Khanam *International Centre for Diarrhoeal Diseases Research, Bangladesh, Dhaka, Bangladesh.
Sabina Dongol *Oxford University Clinical Research Unit, Patan Academy of Health Sciences, Kathmandu, Nepal.
Happy BandaMalawi-Liverpool-Wellcome Programme, Blantyre, Malawi.
Abhilasha KarkeyOxford University Clinical Research Unit, Patan Academy of Health Sciences, Kathmandu, Nepal.
Lorena Preciado-LlanesOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Helena Thomaides-BrearsOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Malick GibaniOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Nazmul Hasan RajibInternational Centre for Diarrhoeal Diseases Research, Bangladesh, Dhaka, Bangladesh.
Nazia RahmanInternational Centre for Diarrhoeal Diseases Research, Bangladesh, Dhaka, Bangladesh.
Prasanta Kumar BiswasInternational Centre for Diarrhoeal Diseases Research, Bangladesh, Dhaka, Bangladesh.
Md Amirul Islam BhuiyanInternational Centre for Diarrhoeal Diseases Research, Bangladesh, Dhaka, Bangladesh.
Sally KayWellcome Sanger Institute, Hinxton, UK.
Kate AugerWellcome Sanger Institute, Hinxton, UK.
Olivier SeretWellcome Sanger Institute, Hinxton, UK.
Nicholas R ThomsonWellcome Sanger Institute, Hinxton, UK.
Andrew J PollardOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Stephen BakerDepartment of Medicine, University of Cambridge, Cambridge, UK.
Buddha BasnyatOxford University Clinical Research Unit, Patan Academy of Health Sciences, Kathmandu, Nepal.
John D ClemensInternational Centre for Diarrhoeal Diseases Research, Bangladesh, Dhaka, Bangladesh.
Christiane DolecekNuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.
Sarah J DunstanDepartment of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Gordon DouganDepartment of Medicine, University of Cambridge, Cambridge, UK.
Robert S HeydermanResearch Department of Infection, Division of Infection and Immunity, University College London, London, UK.
Virginia E PitzerDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, Yale University, New Haven, CT, USA.
Firdausi QadriInternational Centre for Diarrhoeal Diseases Research, Bangladesh, Dhaka, Bangladesh.
Melita A GordonMalawi-Liverpool-Wellcome Programme, Blantyre, Malawi.
Kathryn E Holt *Department of Infectious Diseases, School of Translational Medicine, Monash University, Melbourne, VIC, Australia.
Thomas C Darton *Clinical Infection Research Group, Division of Clinical Medicine, School of Medicine & Population Health, and The Florey Institute for Infection, University of Sheffield, Sheffield, UK.
STRATAA Study Group

Funding

Gates Foundation OPP1141321UK Department of Health and Social Care. NIHR300039Wellcome Trust 106158/Z/14/ZWellcome Trust 206194Wellcome Trust 220540/Z/20/AWellcome Trust 224029/Z/21/Z
6 · The paper itself

Abstract

backgroundTyphoid fever is a systemic infection caused by Salmonella enterica serovar Typhi (S. Typhi) invasion from the gut lumen. Transmission between people occurs through ingestion of contaminated food and water, particularly in settings with poor water and sanitation infrastructure, resulting in over 10 million illnesses annually. As the pathogen invades via the gastrointestinal tract, it is plausible that the gut microbiome may influence the outcome of S. Typhi exposure. There is some evidence that bacteria producing short-chain fatty acids (SCFAs) may create an environment unfavourable to invasive Salmonella, but data from humans is limited.

methodsTo investigate the association between the gut microbiome and typhoid fever, we analysed samples collected from three all-age cohorts enrolled in a prospective surveillance study conducted across three settings where typhoid fever is endemic (Dhaka, Bangladesh; Blantyre, Malawi; and Kathmandu, Nepal). Cohorts consisted of acute typhoid fever patients (n = 92), asymptomatic household contacts of typhoid fever patients (representing individuals who were likely exposed to S. Typhi but did not develop the disease, n = 97) and asymptomatic serosurvey participants with high Vi antibody titres (representing individuals who were exposed to S. Typhi and may be carriers, n = 69). The stool microbiomes of each cohort were characterised using shotgun metagenomics, and bacterial diversity, composition and function were compared.

resultsWe identified 4 bacterial species that were significantly lower in abundance in typhoid fever patients compared with household contacts (i.e. probably exposed), in two of the three participant populations (Bangladesh and Malawi). These bacteria may represent taxa that provide protection against the development of clinical infection upon exposure to S. Typhi and include the inflammation-associated species Prevotella copri clade A and Haemophilus parainfluenzae. Our functional analysis identified 28 specific metabolic gene clusters (MGCs) negatively associated with typhoid fever in Bangladesh and Malawi, including seven MGCs involved in SCFA metabolism. The putative protection provided by microbiome SCFA metabolism was supported by data from a controlled human infection model conducted in a UK population, in which participants who did not develop typhoid fever following ingestion of S. Typhi had a higher abundance of a putative SCFA-metabolising MGC (q-value = 0.22).

conclusionsThis study identified the same protective associations between taxonomic and functional microbiota characteristics and non-susceptibility to typhoid fever across multiple human populations. Future research should explore the potential functional role of SCFAs and inflammation-associated bacteria in resistance to S. Typhi and other enteric infections. Video Abstract.

Indexed as

Gastrointestinal MicrobiomeSalmonella typhiTyphoid FeverAdolescentAdultBangladeshChildChild, PreschoolEndemic DiseasesFatty Acids, VolatileFecesFemaleHumansMalawiMaleMiddle AgedFatty Acids, Volatile

Identifiers

PMID40696437
PMCPMC12281769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.